Growth Hormone Peptides: A Complete Guide

Growth hormone peptides are not one compound. They are two separate families of research molecules that reach the same target, the growth hormone secreting cells of the pituitary gland, by way of two different receptors. If you have seen names like sermorelin, tesamorelin, CJC-1295, ipamorelin, GHRP-2, and GHRP-6 used almost interchangeably, that is the confusion this guide untangles.

This is the start here pillar for LifeConverted's growth hormone and performance category. It walks through the growth hormone axis first, then maps each compound onto the receptor it actually activates, so the mechanism, not the marketing, tells you what a peptide is built to do. One compound in this family, tesamorelin, carries an FDA approved use. Every other named compound here is an investigational research chemical, not an approved therapy, and that distinction holds throughout.

The growth hormone axis, one step at a time

Growth hormone release starts in the hypothalamus, a small region at the base of the brain that acts as a central switchboard for hormone cascades. Neurons there secrete growth hormone releasing hormone, abbreviated GHRH, in short pulses rather than a steady drip. GHRH travels a short distance to the pituitary gland and binds a receptor on specialized cells called somatotrophs. Binding triggers those cells to synthesize and release growth hormone, GH, into the bloodstream. Think of GHRH as a key cut for one lock: it fits the GHRH receptor and nothing else, and turning that lock opens the growth hormone supply line.

The hypothalamus also releases a second signal, somatostatin, that does the opposite job. Somatostatin binds a different pituitary receptor and suppresses GH release. GHRH and somatostatin act as accelerator and brake on the same cells, and the pulsing pattern of GH in blood, high during deep sleep, low for long stretches of the day, reflects which signal has the upper hand at that moment.

A second, independent pathway also drives GH release. Ghrelin, best known as an appetite hormone made in the stomach, activates its own receptor on those same somatotroph cells: the ghrelin receptor, distinct from the GHRH receptor. Ghrelin signaling pushes GH release through a different internal messenger cascade and also blunts somatostatin's braking effect along the way. This second pathway matters because two structurally unrelated signals converge on the same cell type through two separate locks, and a molecule built to fit one lock does not automatically fit the other. A detailed account of this ghrelin pathway appears in a review of pituitary growth hormone regulation hosted by the National Institutes of Health.

Once released, GH travels to the liver and other tissues, where it triggers production of insulin like growth factor 1, IGF-1. IGF-1 is the molecule that carries out much of what people associate with growth hormone: tissue building signals, metabolic effects, and cell growth support. IGF-1 then completes the loop by traveling back to the hypothalamus and pituitary, where it suppresses further GHRH release and stimulates somatostatin. This negative feedback keeps the axis from running unchecked, the same way a thermostat cuts the furnace once a room reaches its set temperature.

The pulsing pattern matters as much as the total amount released. Somatotrophs do not sit at a constant output; they fire in short bursts, largely overnight during deep sleep, separated by quiet stretches where GH in blood drops close to baseline. A steady, unbroken level of circulating GH is not how a healthy axis behaves. This is why the peptides discussed below are built around timing, a short acting compound aimed at sharpening a single pulse, a long acting one aimed at extending a pulse's tail, rather than around simply raising GH continuously.

Two families, one pituitary target

Every growth hormone peptide in research use is built to act on one of the two pathways above. GHRH analogs are engineered versions of the natural GHRH signal: they bind the GHRH receptor and amplify the accelerator. GH releasing peptides, sometimes called ghrelin mimetics or growth hormone secretagogues, bind the ghrelin receptor instead and pull the second lever. Pairing one compound from each family shows up often in research discussions because the two pathways are independent: stimulating both at once produces a larger GH pulse than either pathway alone, an effect researchers describe as synergistic rather than simply additive.

GHRH analogs: sermorelin, tesamorelin, and CJC-1295

Sermorelin is the shortest and most direct GHRH analog in common research use. It reproduces the first 29 amino acids of natural GHRH, the fragment shown to retain full receptor binding activity, so it behaves like a close copy of the body's own signal with a short half life measured in minutes. Because it clears quickly, its GH release pattern in research settings looks like a single pulse rather than a sustained elevation.

Tesamorelin is a stabilized GHRH analog with one meaningful difference from the rest of this guide: it is FDA approved, sold under the brand name Egrifta, for reducing excess abdominal fat in adults with HIV associated lipodystrophy, a fat redistribution condition linked to the virus and its treatment. The FDA prescribing information lays out that approved indication and the dosing studied in that population. Outside that specific approved use, tesamorelin remains a research compound, and this guide does not extend its approval to any other purpose.

CJC-1295 without DAC is a modified GHRH analog built for a longer half life than sermorelin, commonly cited around 30 minutes, without the drug affinity complex described next. Researchers reach for it where a stronger single pulse than sermorelin is the goal, without the multi day duration of the DAC version.

CJC-1295 with DAC adds a drug affinity complex, a chemical handle that binds circulating albumin, the most abundant protein in blood plasma. That binding works like an anchor: the peptide rides along with albumin instead of being cleared quickly by the kidneys, stretching its active window from minutes to days. A study in healthy adults found that subcutaneous CJC-1295 with DAC produced sustained, dose dependent increases in both GH and IGF-1 over multiple days following a single dose.

GH releasing peptides: the ghrelin mimetic family

GHRP-6 was one of the first ghrelin receptor peptides studied and remains a reference point for the class. Like ghrelin itself, it stimulates appetite alongside GH release, a side effect that follows directly from sharing ghrelin's receptor rather than acting as a separate, unrelated effect.

GHRP-2 activates the same receptor with a stronger GH releasing effect per dose than GHRP-6 in research comparisons, alongside a milder appetite effect. Early ghrelin mimetics like GHRP-2 and GHRP-6 also tend to raise cortisol and prolactin together with GH, a side effect profile that later compounds in this family were designed to narrow.

Ipamorelin was developed specifically to narrow that profile. It is a five amino acid peptide, a pentapeptide, that activates the ghrelin receptor with what researchers describe as a selective effect: in the study that first characterized it, ipamorelin released GH without a meaningful rise in ACTH or cortisol, even at doses far above what was needed for GH release. That selectivity is the main reason ipamorelin appears so often paired with a GHRH analog in research discussions rather than the older GHRP compounds.

Hexarelin sits at the potent end of the ghrelin mimetic family. It produces a strong GH release, and separate animal research has also examined a receptor independent effect on heart tissue that has nothing to do with growth hormone at all, a reminder that a peptide's name does not guarantee one tidy mechanism.

Downstream and adjacent: IGF-1 LR3, MGF, and PEG MGF

A few related compounds show up in the same research conversations without acting on the GH axis itself, and they are worth separating out clearly. IGF-1 LR3 is a modified version of IGF-1, the downstream molecule from the feedback loop described earlier, not a GHRH or ghrelin receptor peptide. The modification extends its activity window compared to native IGF-1. MGF, mechano growth factor, is a splice variant of IGF-1 that research has linked to local tissue repair signaling rather than systemic GH release. PEG MGF is a stabilized version of MGF built for a longer active window, using the same albumin binding logic described for CJC-1295 with DAC. None of these three acts through the GHRH receptor or the ghrelin receptor, and none carries an FDA approved use. They belong in this guide because researchers studying the growth hormone axis frequently study these downstream compounds in the same breath, not because they share a mechanism with sermorelin or ipamorelin. Direct recombinant HGH is a separate approach again: it supplies growth hormone itself and bypasses the pituitary entirely, rather than nudging the axis to release more of its own.

What the current research actually shows

The evidence base across this category is uneven, and that unevenness matters more than any single finding. Tesamorelin has the strongest human evidence, backed by randomized trials that led to FDA approval for one specific population. Sermorelin, CJC-1295, and ipamorelin each have supporting human research on their acute effects on GH and IGF-1 levels, mostly from small trials measuring blood hormone levels over hours or days rather than long term outcomes. GHRP-2, GHRP-6, and hexarelin carry a longer research history but with less modern trial data behind them. Combination use, such as pairing a GHRH analog with a ghrelin mimetic, comes up constantly in informal research discussion but has little to no dedicated trial data behind the specific pairing itself, even where each individual compound is well studied on its own. None of this supports treating any compound here, other than tesamorelin in its approved population, as a medical therapy.

Reading a study honestly means checking three things before accepting a claim about any compound in this guide: how many people or animals it enrolled, how long they were followed, and what was actually measured. A trial that tracked hormone levels in blood for a few days tells you about a pulse, not about years of use. A study run in rodents tells you about a mechanism worth investigating in humans, not about a confirmed human effect. Most of the research behind sermorelin, CJC-1295, ipamorelin, and the GHRP compounds sits in that first category: short, mechanism focused, and informative about how the axis responds, without settling questions about extended use.

If you are trying to place a specific compound, dose form, or research blend within this landscape, LifeConverted's full peptide reference library covers each one individually with its own mechanism notes.

Common questions

Is tesamorelin the only FDA approved growth hormone peptide?

Yes, within this family. Tesamorelin, sold as Egrifta, is FDA approved only for reducing visceral fat in adults with HIV associated lipodystrophy. Sermorelin, CJC-1295, ipamorelin, GHRP-2, GHRP-6, hexarelin, IGF-1 LR3, MGF, and PEG MGF are all investigational research compounds without FDA approval for any use.

What is the practical difference between a GHRH analog and a GH releasing peptide?

A GHRH analog binds the GHRH receptor and amplifies the body's natural growth hormone releasing hormone signal. A GH releasing peptide, also called a ghrelin mimetic, binds a separate receptor, the ghrelin receptor, and pulls GH release through a different internal pathway. Researchers often study the two together because the receptors work independently.

Why does ipamorelin get described as more selective than GHRP-2 or GHRP-6?

In the research that first characterized it, ipamorelin activated the ghrelin receptor and released GH without meaningfully raising cortisol or ACTH, even at high doses. Older ghrelin mimetics like GHRP-2 and GHRP-6 tend to raise those hormones alongside GH, an effect researchers consider less selective.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.